Abstract
Efforts to develop and refine percutaneous approaches to cardiac valve repair and replacement have advanced rapidly over the past several years, having exceeded even the most optimistic expectations. New innovations have been predominantly directed toward the most frequent form of valvular heart disease (VHD) in the industrialized world; aortic stenosis (AS). Approximately 250,000 transcatheter aortic valve implantation (TAVI) procedures have been done so far addressing this significant medical need.
Because of the predominance of degenerative etiologies, the prevalence of VHD increases markedly in population above the age of 65 years, in particular with regard to severe AS. As the populations of the industrialized countries continue to be older, the need for less invasive and safer methods of treating severe AS will continue to grow.
In this review we provide comprehensive and up-to-date overview of TAVI in current clinical practice. We have also addressed dilemmas and unanswered questions related to TAVI procedures in different groups of patients and highlighted opportunities and trends related to future TAVI implementation.
Keywords: Aortic stenosis, TAVI, future trends, cardiac valve, heart disease, aortic stenosis.
Current Pharmaceutical Design
Title:Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends
Volume: 23 Issue: 31
Author(s): Marko Banovic*, Jozef Bartunek, Serge D. Nikolic, Vladan Vukcevic, Srdjan Aleksandric and Bernard Iung
Affiliation:
- Cardiology Department, University Clinical Center of Serbia, Belgrade,Serbia
Keywords: Aortic stenosis, TAVI, future trends, cardiac valve, heart disease, aortic stenosis.
Abstract: Efforts to develop and refine percutaneous approaches to cardiac valve repair and replacement have advanced rapidly over the past several years, having exceeded even the most optimistic expectations. New innovations have been predominantly directed toward the most frequent form of valvular heart disease (VHD) in the industrialized world; aortic stenosis (AS). Approximately 250,000 transcatheter aortic valve implantation (TAVI) procedures have been done so far addressing this significant medical need.
Because of the predominance of degenerative etiologies, the prevalence of VHD increases markedly in population above the age of 65 years, in particular with regard to severe AS. As the populations of the industrialized countries continue to be older, the need for less invasive and safer methods of treating severe AS will continue to grow.
In this review we provide comprehensive and up-to-date overview of TAVI in current clinical practice. We have also addressed dilemmas and unanswered questions related to TAVI procedures in different groups of patients and highlighted opportunities and trends related to future TAVI implementation.
Export Options
About this article
Cite this article as:
Banovic Marko *, Bartunek Jozef , Nikolic D. Serge , Vukcevic Vladan , Aleksandric Srdjan and Iung Bernard , Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612822666161018162022
DOI https://dx.doi.org/10.2174/1381612822666161018162022 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias
Current Pharmaceutical Design Endothelial Function Assessment in Complicated Hypertension
Current Pharmaceutical Design Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Subject Index To Volume 7
Current Pharmaceutical Design Fatty Acids in Marine Organisms: In the Pursuit of Bioactive Agents
Current Pharmaceutical Analysis Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets SAR and QSAR of the Antioxidant Activity of Flavonoids
Current Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Functional Null Mutations in the Gonosomal Homologue Gene TBL1Y are Associated with Non-Syndromic Coarctation of the Aorta
Current Molecular Medicine High Doses of In vitro Beta-carotene, Alpha-Tocopherol and Ascorbic Acid Induce Oxidative Stress and Secretion of IL-6 in Peripheral Blood Mononuclear Cells from Healthy Donors
Current Aging Science Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism